novo nordisk chronic kidney disease

Novo Nordisk’s Ozempic Gets FDA Approval

FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use

Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves a gradual loss of kidney function.

Reuters · 2d

US FDA approves Novo Nordisk's Ozempic to cut risk of diabetic kidney disease progression

The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with chronic kidney disease (CKD),

The Wall Street Journal on MSN · 2d

Novo Nordisk’s Ozempic Gets FDA Approval as Kidney-Disease Treatment

Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type 2 diabetes and chronic kidney disease, Novo Nordisk said.

2don MSN

Novo Nordisk's Ozempic gets FDA approval for kidney disease

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, or semaglutide, has been approved for the treatment of patients ...

pharmaphorum1h

Two more biotechs, Metsera and Maze, cross IPO finish line

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the ...

MM&M15h

Rx Rundown: Merck, Biogen, Pfizer and more

HonorHealth announced the creation of its new international Center for Translational Science. Sanofi said it will repurchase $5.2 billion of stock and grow profits faster this year as the drugmaker ...

22h

Novo Nordisk will test CagriSema's long-term efficacy in late-stage trial, clinicaltrials.gov entry shows

Novo Nordisk will begin a new late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10, according to a entry.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results